Peptides
Ovagen (EDL): kidney findings in rats, no verified human benefit
What is it?
Ovagen is used as a marketing name for the Glu-Asp-Leu (EDL) short peptide in bioregulator literature. It is unrelated to similarly named veterinary ovulation products. The peptide’s identity in a particular supplier vial still depends on analytical verification. [1]
What do studies show?
A preclinical study gave EDL and related peptides to rats with cisplatin-induced acute renal failure and reported changes in urine output, creatinine handling, filtration, and electrolyte measures. The design supports a kidney-injury research hypothesis, not a finding that Ovagen prevents or treats human kidney disease. Liver-support claims have even less direct clinical support. Manufacturer brochures discuss human use but are not a substitute for an accessible controlled trial of the exact vial. [1,2]
Safety
Kidney and liver illness can be serious and require measured laboratory evaluation and cause-specific treatment. The rat study cannot establish safety in patients with impaired organ function or verify sterility and purity of an online vial.
DOSE STATUS
How much?
EVIDENCE CONTEXT
Why?
The cited evidence does not establish a dose for this use or product.
No effective and safe human Ovagen dose has been established. Rat-study amounts and oral supplement brochures cannot be converted to an injectable EDL regimen, and the vial’s mass is not a dose. No exact-product anecdotal protocol with a verifiable source and route was found. [1,2]